{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yerushalmy-Feler A"],"funding":["NIDDK NIH HHS"],"pagination":["jjae182"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12548835"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(5)"],"pubmed_abstract":["<h4>Background and aims</h4>Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as an induction therapy in pediatric UC or IBD-U.<h4>Methods</h4>In this multicenter retrospective study, children treated with upadacitinib for induction of remission of active UC or IBD-U from 30 centers worldwide were enrolled. Demographic, clinical, and laboratory data, as well as adverse events (AEs), were recorded at Week 8 post-induction.<h4>Results</h4>One hundred children were included (90 UC and 10 IBD-U, median age 15.6 [interquartile range 13.3-17.1] years). Ninety-eight were previously treated with biologic therapies, and 76 were treated with ≥2 biologic"],"journal":["Journal of Crohn's & colitis"],"pubmed_title":["Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study."],"pmcid":["PMC12548835"],"funding_grant_id":["K23 DK119585"],"pubmed_authors":["Urlep D","Ancona S","Uhlig HH","Yerushalmy-Feler A","Granot M","Wlazlo M","Yogev D","Hradsky O","Hojsak I","Turner D","Rinawi F","Rungo C","Mitrova K","Kang B","Shouval DS","Olbjorn C","Hackl L","Sansotta N","Tzivinikos C","Magen Rimon R","Suskind DL","Trindade E","Spencer EA","Conrad MA","Norsa L","Pujol-Muncunill G","Cohen S","Kolho KL","Scarallo L","Velasco Rodriguez-Belvis M","Bramuzzo M","Gasparetto M","D'Arcangelo G","Dolinger MT","Kelsen JR"],"additional_accession":[]},"is_claimable":false,"name":"Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study.","description":"<h4>Background and aims</h4>Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as an induction therapy in pediatric UC or IBD-U.<h4>Methods</h4>In this multicenter retrospective study, children treated with upadacitinib for induction of remission of active UC or IBD-U from 30 centers worldwide were enrolled. Demographic, clinical, and laboratory data, as well as adverse events (AEs), were recorded at Week 8 post-induction.<h4>Results</h4>One hundred children were included (90 UC and 10 IBD-U, median age 15.6 [interquartile range 13.3-17.1] years). Ninety-eight were previously treated with biologic therapies, and 76 were treated with ≥2 biologic","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-04T16:38:14.856Z","creation":"2026-05-13T14:24:39.086Z"},"accession":"S-EPMC12548835","cross_references":{"pubmed":["39605286"],"doi":["10.1093/ecco-jcc/jjae182"]}}